Hematology Program
Smilow Cancer Hospital at Yale New Haven
35 Park Street
New Haven, CT 06511
- Hematology ProgramSmilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
Lourdes Mendez, MD, PhD
Hematology, Hematologic Oncology
Patient type treated
Adult
Accepting new patients
Yes
Referral required
Not Applicable
Biography
Lourdes Mendez, MD, PhD, is a hematologic oncologist specializing in the treatment of leukemia, particularly acute lymphoblastic leukemia.
As an assistant professor at Yale School of Medicine, Dr. Mendez is involved in research that seeks to develop new therapeutic options for leukemia and myeloid disorders (a group of blood cancers that affect the bone marrow’s ability to produce healthy blood cells). Her research aims to translate laboratory findings into clinical applications to enhance patient care.
Dr. Mendez received her medical training from Albert Einstein College of Medicine and completed her residency at Weill Cornell-New York Presbyterian. She pursued a fellowship in hematology and oncology at Beth Israel Deaconess Medical Center, where she also completed a postdoctoral fellowship in cancer genetics.
Titles
- Assistant Professor
Education & Training
- Research FellowBeth Israel Deaconess Medical Center (2017)
- Clinical Fellow in Hematology/OncologyBeth Israel Deaconess Medical Center (2014)
- ResidentWeill Cornell-New York Presbyterian (2011)
- InternWeill Cornell-New York Presbyterian (2009)
- PhDAlbert Einstein College of Medicine, Cell Biology
- MDAlbert Einstein College of Medicine
Languages Spoken
- English
- Español (Spanish)
Additional Information
Professional Service
- American Society of Hematology (2007 - Present): Member
Publications
- Ito S, Potnis K, Ng D, Patel K, Sra M, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Huntington S, Stahl M, Zeidan A, Bewersdorf J, Goshua G. Cost-effectiveness of frontline eltrombopag with immunosuppressive therapy for severe aplastic anemia. Blood Red Cells & Iron 2026, 2: 100076. PMID: 42077391, PMCID: PMC13134686, DOI: 10.1016/j.brci.2026.100076.
- Aguirre L, Bewersdorf J, Liu Y, Shallis R, Boussi L, Zucenka A, Garciaz S, Bystrom R, DeAngelo D, Stone R, Luskin M, Garcia J, Winer E, Ling K, Chen E, Wadleigh M, Berton G, Stein E, Goldberg A, Mendez L, Zeidan A, Sallman D, Shimony S, Stahl M. Comparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogenetics. Blood Neoplasia 2026, 3: 100201. PMID: 41859348, PMCID: PMC12997325, DOI: 10.1016/j.bneo.2026.100201.
- Gong G, Liu J, Pandya S, Taborda C, Wiesendanger N, Price N, Byron W, Coppi A, Young P, Wiess C, Dunning H, Barganier C, Brodeur R, Fischbach N, LoRusso P, Pusztai L, Kim S, Rozenblit M, Cecchini M, Mongiu A, Mendez L, Kaftan E, Torre C, Krumholz H, Krop I, Schulz W, Lustberg M, Kunz P. Clinical Trial Patient Matching: A Real-Time, Common Data Model and Artificial Intelligence–Driven System for Semiautomated Patient Prescreening in Cancer Clinical Trials. JCO Clinical Cancer Informatics 2026, 10: e2500262. PMID: 41512229, DOI: 10.1200/cci-25-00262.
- Alhajahjeh A, Woite N, Rolles B, Stempel J, Mina A, Mendez L, Kewan T, Podoltsev N, Stahl M, Grimshaw A, Zeidan A, Bewersdorf J. Luspatercept for patients with lower-risk myelodysplastic syndromes/neoplasms: a systematic review and meta-analysis. Blood Advances 2025, 9: 6511-6523. PMID: 40966428, PMCID: PMC12767819, DOI: 10.1182/bloodadvances.2025017611.
- Hunter C, Chou A, Roeder H, Eighmy W, Bewersdorf J, Mendez L, Stahl M, Podoltsev N, Zeidan A, Shallis R. Isavuconazole provides effective and tolerable antifungal prophylaxis for patients with acute myeloid leukemia. Leukemia Research 2025, 160: 108144. PMID: 41365214, DOI: 10.1016/j.leukres.2025.108144.
- Hunter C, Cheng W, Bewersdorf J, Boddu P, Browning S, Halene S, Parker T, Huntington S, Kothari S, Mendez L, Neparidze N, Sethi T, Barbarotta L, Podoltsev N, Zeidan A, Shallis R. Feasibility, safety and outcomes of patients with newly diagnosed acute myeloid leukemia discharged ‘early’ after intensive induction. Leukemia & Lymphoma 2025, 67: 164-175. PMID: 41160735, DOI: 10.1080/10428194.2025.2578420.
- Author Correction: An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancerChen M, Zhang J, Sampieri K, Clohessy J, Mendez L, Gonzalez-Billalabeitia E, Liu X, Lee Y, Fung J, Katon J, Menon A, Webster K, Ng C, Palumbieri M, Diolombi M, Breitkopf S, Teruya-Feldstein J, Signoretti S, Bronson R, Asara J, Castillo-Martin M, Cordon-Cardo C, Pandolfi P. Author Correction: An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer. Nature Genetics 2025, 57: 2931-2931. PMID: 41125873, DOI: 10.1038/s41588-025-02394-w.
- Alhajahjeh A, Patel K, Podoltsev N, Kewan T, Stempel J, Mendez L, Seropian S, Gowda L, Huntington S, Stahl M, Zeidan A, Goshua G, Bewersdorf J. Cost-effectiveness of upfront vs delayed allogeneic hematopoietic stem cell transplant for intermediate risk AML. Blood Advances 2025, 9: 5234-5246. PMID: 40720773, PMCID: PMC12550792, DOI: 10.1182/bloodadvances.2025016532.
- Wang R, Stempel J, Shallis R, Huntington S, Zeidan A, Neparidze N, Di M, Bewersdorf J, Mendez L, Ma X, Podoltsev N. Second malignancies among older patients with classical myeloproliferative neoplasms treated with ruxolitinib. Blood Neoplasia 2025, 2: 100159. PMID: 41216598, PMCID: PMC12597058, DOI: 10.1016/j.bneo.2025.100159.
- Hidalgo Cedeno E, Germans S, Pan Z, Mendez L, Weinberg O, Xu M. PAX5 as a diagnostic tool in unconventional acute leukemia: Establishing immunohistochemical evidence of B-cell lineage. Human Pathology 2025, 163: 105903. PMID: 40782987, DOI: 10.1016/j.humpath.2025.105903.
- Bewersdorf J, Hasle V, Shallis R, Thompson E, de Menezes D, Rose S, Boss I, Mendez L, Podoltsev N, Stahl M, Kewan T, Halene S, Haferlach T, Fox B, Zeidan A. Integrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine ± Durvalumab. Therapeutic Advances In Hematology 2025, 16: 20406207251347344. PMID: 40546817, PMCID: PMC12182606, DOI: 10.1177/20406207251347344.
- Mendez L, DeAngelo D, Luskin M. Treatment of Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. Acta Haematologica 2025, 149: 61-75. PMID: 40494331, DOI: 10.1159/000546381.
- Yang M, Boye-Doe A, Ali M, Abosabie S, Barr A, Mendez L, Sharda A. RalB uncoupling from exocyst is required for endothelial Weibel-Palade body exocytosis. Molecular Biology Of The Cell 2025, 36: ar62. PMID: 40172988, PMCID: PMC12086567, DOI: 10.1091/mbc.e24-11-0493.
- Alhajahjeh A, Patel K, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Huntington S, Stahl M, Goshua G, Bewersdorf J, Zeidan A. Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AML. Leukemia & Lymphoma 2024, 66: 488-496. PMID: 39560957, PMCID: PMC12138910, DOI: 10.1080/10428194.2024.2426073.
- A review of the isocitrate dehydrogenase inhibitors in management of adult patients with AML and MDSNorman M, Yamartino K, Gerstein R, Shallis R, Mendez L, Podoltsev N, Stahl M, Eighmy W, Zeidan A. A review of the isocitrate dehydrogenase inhibitors in management of adult patients with AML and MDS. Expert Review Of Hematology 2024, 17: 755-767. PMID: 39474840, DOI: 10.1080/17474086.2024.2422554.
- Alhajahjeh A, Rotter L, Stempel J, Grimshaw A, Bewersdorf J, Blaha O, Kewan T, Podoltsev N, Shallis R, Mendez L, Stahl M, Zeidan A. Global Disparities in the Characteristics and Outcomes of Leukemia Clinical Trials: A Cross-Sectional Study of the ClinicalTrials.gov Database. JCO Global Oncology 2024, 10: e2400316. PMID: 39621951, DOI: 10.1200/go-24-00316.
- Rotter L, Alhajahjeh A, Stempel J, Grimshaw A, Bewersdorf J, Blaha O, Kewan T, Podoltsev N, Shallis R, Mendez L, Stahl M, Zeidan A. Analyzing determinants of premature trial discontinuation in leukemia clinical trials. Leukemia & Lymphoma 2024, 66: 289-297. PMID: 39440622, DOI: 10.1080/10428194.2024.2416565.
- Xie Z, Komrokji R, Al Ali N, Regelson A, Geyer S, Patel A, Saygin C, Zeidan A, Bewersdorf J, Mendez L, Kishtagari A, Zeidner J, Coombs C, Madanat Y, Chung S, Badar T, Foran J, Desai P, Tsai C, Griffiths E, Al Malki M, Amanam I, Lai C, Deeg H, Ades L, Arana Yi C, Osman A, Dinner S, Abaza Y, Taylor J, Chandhok N, Soong D, Brunner A, Carraway H, Singh A, Elena C, Ferrari J, Gallì A, Pozzi S, Padron E, Patnaik M, Malcovati L, Savona M, Al-Kali A. Risk prediction for clonal cytopenia: multicenter real-world evidence. Blood 2024, 144: 2033-2044. PMID: 38996210, PMCID: PMC11561536, DOI: 10.1182/blood.2024024756.
- Taborda C, Zeidan A, Mendez L. Clonal cytopenia of undetermined significance: definitions, risk and therapeutic targets. Frontiers In Hematology 2024, 3: 1419323. DOI: 10.3389/frhem.2024.1419323.
- Bewersdorf J, Patel K, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Stahl M, Stein E, Huntington S, Goshua G, Zeidan A. Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3-mutant acute myeloid leukemia. Leukemia & Lymphoma 2024, 65: 1136-1144. PMID: 38648559, PMCID: PMC11265977, DOI: 10.1080/10428194.2024.2344052.
- Shallis R, Wang R, Zeidan A, Huntington S, Neparidze N, Stempel J, Mendez L, Di M, Ma X, Podoltsev N. Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence. Blood Advances 2023, 7: 3213-3224. PMID: 36939371, PMCID: PMC10338212, DOI: 10.1182/bloodadvances.2022009074.
- Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid NeoplasmsXie Z, Chen E, Mendez L, Komrokji R, Zeidan A. Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms. The Cancer Journal 2023, 29: 130-137. PMID: 37195768, DOI: 10.1097/ppo.0000000000000656.
- Mendez L, Patnaik M. Clonal Hematopoiesis: Origins and determinants of evolution. Leukemia Research 2023, 129: 107076. PMID: 37075557, DOI: 10.1016/j.leukres.2023.107076.
- VanOudenhove J, Halene S, Mendez L. Is it the time to integrate novel sequencing technologies into clinical practice? Current Opinion In Hematology 2022, 30: 70-77. PMID: 36602939, DOI: 10.1097/moh.0000000000000754.
- Garcia J, Flamand Y, Penter L, Keng M, Tomlinson B, Mendez L, Koller P, Cullen N, Arihara Y, Pfaff K, Wolff J, Brunner A, Galinsky I, Bashey A, Antin J, Cutler C, Ho V, Jonas B, Luskin M, Wadleigh M, Winer E, Savell A, Leonard R, Robertson T, Davids M, Streicher H, Rodig S, Ritz J, Wu C, DeAngelo D, Neuberg D, Stone R, Soiffer R. Ipilimumab plus decitabine for patients with MDS or AML in post-transplant or transplant naïve settings. Blood 2022, 141: 1884-1888. PMID: 36332187, PMCID: PMC10122101, DOI: 10.1182/blood.2022017686.
- Daver N, Montesinos P, Aribi A, Martinelli G, Altman J, Wang E, Roboz G, Burke P, Gaidano G, Walter R, Thomas X, Jeyakumar D, DeAngelo D, Erba H, Todisco E, Begna K, Advani A, Gastaud L, de la Fuente A, Curti A, Mendez L, Vyas P, Boissel N, Vey N, Recher C, Longval T, Platzbecker U, Kapp-Schwörer S, Schliemann C, Konopleva M, Torres L, Sallman D, Marcucci G, Marconi G, Kantarjian H, Sloss C, Malcolm K, Zweidler-McKay P, Sweet K. Poster: AML-262 Pivekimab Sunirine (PVEK, IMGN632) Triplet With Azacitidine and Venetoclax Shows Broad Activity in Adverse Genetic Subsets of Relapsed/Refractory Acute Myeloid Leukemia and Reduced Infusion-Related Reactions. Clinical Lymphoma Myeloma & Leukemia 2022, 22: s132. DOI: 10.1016/s2152-2650(22)00792-3.
- Daver N, Montesinos P, Aribi A, Martinelli G, Altman J, Wang E, Roboz G, Burke P, Gaidano G, Walter R, Thomas X, Jeyakumar D, DeAngelo D, Erba H, Todisco E, Begna K, Advani A, Gastaud L, de la Fuente A, Curti A, Mendez L, Vyas P, Boissel N, Vey N, Recher C, Longval T, Platzbecker U, Kapp-Schwörer S, Schliemann C, Konopleva M, Torres L, Sallman D, Marcucci G, Marconi G, Kantarjian H, Sloss C, Malcolm K, Zweidler-McKay P, Sweet K. AML-262 Pivekimab Sunirine (PVEK, IMGN632) Triplet With Azacitidine and Venetoclax Shows Broad Activity in Adverse Genetic Subsets of Relapsed/Refractory Acute Myeloid Leukemia and Reduced Infusion-Related Reactions. Clinical Lymphoma Myeloma & Leukemia 2022, 22: s231-s232. DOI: 10.1016/s2152-2650(22)01257-5.
- Brunner A, Liu Y, Mendez L, Garcia J, Amrein P, Neuberg D, Dean E, Smith S, Stone R, Fathi A, Walter M, Graubert T, Jacoby M. P758: INHIBITION OF ATR WITH CERALASERTIB (AZD6738) FOR THE TREATMENT OF PROGRESSIVE OR RELAPSED MYELODYSPLASTIC SYNDROMES AND CHRONIC MYELOMONOCYTIC LEUKEMIA: A PHASE IB/II STUDY. HemaSphere 2022, 6: 653-654. DOI: 10.1097/01.hs9.0000845916.12740.98.
- Kukkula A, Ojala V, Mendez L, Sistonen L, Elenius K, Sundvall M. Therapeutic Potential of Targeting the SUMO Pathway in Cancer. Cancers 2021, 13: 4402. PMID: 34503213, PMCID: PMC8431684, DOI: 10.3390/cancers13174402.
- Sharda A, Bogue T, Barr A, Mendez L, Flaumenhaft R, Zwicker J. Circulating Protein Disulfide Isomerase Is Associated with Increased Risk of Thrombosis in JAK2-Mutated Myeloproliferative NeoplasmsPlasma PDI and Thrombosis in MPN. Clinical Cancer Research 2021, 27: 5708-5717. PMID: 34400417, PMCID: PMC9170286, DOI: 10.1158/1078-0432.ccr-21-1140.
- Sharda A, Barr A, Harrison J, Wilkie A, Fang C, Mendez L, Ghiran I, Italiano J, Flaumenhaft R. VWF maturation and release are controlled by 2 regulators of Weibel-Palade body biogenesis: exocyst and BLOC-2. Blood 2020, 136: 2824-2837. PMID: 32614949, PMCID: PMC7731791, DOI: 10.1182/blood.2020005300.
- Brunner A, Blonquist T, DeAngelo D, McMasters M, Fell G, Hermance N, Winer E, Lindsley R, Hobbs G, Amrein P, Hock H, Steensma D, Garcia J, Luskin M, Stone R, Ballen K, Rosenblatt J, Avigan D, Nahas M, Mendez L, McAfee S, Moran J, Bergeron M, Foster J, Bertoli C, Manning A, McGregor K, Fishman K, Kuo F, Baltay M, Macrae M, Burke M, Behnan T, Wey M, Som T, Ramos A, Rae J, Lombardi Story J, Nelson N, Logan E, Connolly C, Neuberg D, Chen Y, Graubert T, Fathi A. Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. The Lancet Haematology 2019, 7: e122-e133. PMID: 31837959, PMCID: PMC10354959, DOI: 10.1016/s2352-3026(19)30203-0.
- Mendez L, Posey R, Pandolfi P. The Interplay Between the Genetic and Immune Landscapes of AML: Mechanisms and Implications for Risk Stratification and Therapy. Frontiers In Oncology 2019, 9: 1162. PMID: 31781488, PMCID: PMC6856667, DOI: 10.3389/fonc.2019.01162.
- Nachmani D, Bothmer A, Grisendi S, Mele A, Bothmer D, Lee J, Monteleone E, Cheng K, Zhang Y, Bester A, Guzzetti A, Mitchell C, Mendez L, Pozdnyakova O, Sportoletti P, Martelli M, Vulliamy T, Safra M, Schwartz S, Luzzatto L, Bluteau O, Soulier J, Darnell R, Falini B, Dokal I, Ito K, Clohessy J, Pandolfi P. Germline NPM1 mutations lead to altered rRNA 2′-O-methylation and cause dyskeratosis congenita. Nature Genetics 2019, 51: 1518-1529. PMID: 31570891, PMCID: PMC6858547, DOI: 10.1038/s41588-019-0502-z.
- Mugoni V, Panella R, Cheloni G, Chen M, Pozdnyakova O, Stroopinsky D, Guarnerio J, Monteleone E, Lee J, Mendez L, Menon A, Aster J, Lane A, Stone R, Galinsky I, Zamora J, Lo-Coco F, Bhasin M, Avigan D, Longo L, Clohessy J, Pandolfi P. Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy. Cell Research 2019, 29: 446-459. PMID: 31024166, PMCID: PMC6796925, DOI: 10.1038/s41422-019-0162-7.
- Chen M, Zhang J, Sampieri K, Clohessy J, Mendez L, Gonzalez-Billalabeitia E, Liu X, Lee Y, Fung J, Katon J, Menon A, Webster K, Ng C, Palumbieri M, Diolombi M, Breitkopf S, Teruya-Feldstein J, Signoretti S, Bronson R, Asara J, Castillo-Martin M, Cordon-Cardo C, Pandolfi P. An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer. Nature Genetics 2018, 50: 206-218. PMID: 29335545, PMCID: PMC6714980, DOI: 10.1038/s41588-017-0027-2.
- Chen M, Wan L, Zhang J, Zhang J, Mendez L, Clohessy J, Berry K, Victor J, Yin Q, Zhu Y, Wei W, Pandolfi P. Deregulated PP1α phosphatase activity towards MAPK activation is antagonized by a tumor suppressive failsafe mechanism. Nature Communications 2018, 9: 159. PMID: 29335436, PMCID: PMC5768788, DOI: 10.1038/s41467-017-02272-y.
- Guarnerio J, Mendez L, Asada N, Menon A, Fung J, Berry K, Frenette P, Ito K, Pandolfi P. A non-cell-autonomous role for Pml in the maintenance of leukemia from the niche. Nature Communications 2018, 9: 66. PMID: 29302031, PMCID: PMC5754357, DOI: 10.1038/s41467-017-02427-x.
- Mendez L, Chen M, Pandolfi P. Molecular Genetics of APL. 2017, 41-53. DOI: 10.1007/978-3-319-64257-4_4.
- Pyzer AR, Stroopinsky D, Rosenblatt J, Anastasiadou E, Rajabi H, Washington A, Tagde A, Chu JH, Coll M, Jiao AL, Tsai LT, Tenen DE, Cole L, Palmer K, Ephraim A, Leaf RK, Nahas M, Apel A, Bar-Natan M, Jain S, McMasters M, Mendez L, Arnason J, Raby BA, Slack F, Kufe D, Avigan D. MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs. Leukemia 2017, 31: 2780-2790. PMID: 28555079, PMCID: PMC5791150, DOI: 10.1038/leu.2017.163.
- Pyzer A, Stroopinsky D, Rajabi H, Washington A, Tagde A, Coll M, Fung J, Bryant M, Cole L, Palmer K, Somaiya P, Karp Leaf R, Nahas M, Apel A, Jain S, McMasters M, Mendez L, Levine J, Joyce R, Arnason J, Pandolfi P, Kufe D, Rosenblatt J, Avigan D. MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia. Blood 2017, 129: 1791-1801. PMID: 28126925, PMCID: PMC5813734, DOI: 10.1182/blood-2016-07-730614.
- Mendez L, Sharda A, Zwicker J. Thrombophilia and Thrombocytopenia in the Pregnant Woman. 2017, 55-76. DOI: 10.1007/978-3-319-39328-5_4.
- Molecular Genetics of Acute Promyelocytic LeukemiaMendez LM, Chen M, Pandolfi PP. Molecular Genetics of Acute Promyelocytic Leukemia. In: Abla, Oussama, Lo Coco, Francesco, Sanz, Miguel A, editors. Acute Promyelocytic Leukemia. Springer 2018.
- Thrombophilia and Thrombocytopenia in the Pregnant WomanMendez LM, Sharda AV, Zwicker JI. Thrombophilia and Thrombocytopenia in the Pregnant Woman. In: Bernstein C, Takoudes T, editors. Medical Problems During Pregnancy. Springer: 2017
- Cerchietti LC, Hatzi K, Caldas-Lopes E, Yang SN, Figueroa ME, Morin RD, Hirst M, Mendez L, Shaknovich R, Cole PA, Bhalla K, Gascoyne RD, Marra M, Chiosis G, Melnick A. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. J Clin Invest 2010, 120: 4569-82. PMID: 21041953, DOI: 10.1172/JCI42869.
- Mendez LM, Polo JM, Yu JJ, Krupski M, Ding BB, Melnick A, Ye BH. CtBP is an essential corepressor for BCL6 autoregulation. Mol Cell Biol 2008, 28: 2175-86. PMID: 18212045, DOI: 10.1128/MCB.01400-07.
- Ding BB, Yu JJ, Yu RY, Mendez LM, Shaknovich R, Zhang Y, Cattoretti G, Ye BH. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 2008, 111: 1515-23. PMID: 17951530, DOI: 10.1182/blood-2007-04-087734.
- Wang X, Ding BB, Mendez LM, Papetti M, Ye BH. Re: Torlakovic et al. PU.1 protein expression has a positive linear association with protein expression of germinal centre B cell genes including BCL-6, CD10, CD20 and CD22: identification of PU.1 putative binding sites in the BCL-6 promotor. J Pathol 2005;206:312-319. J Pathol 2006, 210: 130-1; author reply 132. PMID: 16841370, DOI: 10.1002/path.2031.
Departments and Programs
Locations
Hematology Program
Smilow Cancer Hospital at Yale New Haven
35 Park Street
New Haven, CT 06511
- Hematology ProgramSmilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
Biography
Lourdes Mendez, MD, PhD, is a hematologic oncologist specializing in the treatment of leukemia, particularly acute lymphoblastic leukemia.
As an assistant professor at Yale School of Medicine, Dr. Mendez is involved in research that seeks to develop new therapeutic options for leukemia and myeloid disorders (a group of blood cancers that affect the bone marrow’s ability to produce healthy blood cells). Her research aims to translate laboratory findings into clinical applications to enhance patient care.
Dr. Mendez received her medical training from Albert Einstein College of Medicine and completed her residency at Weill Cornell-New York Presbyterian. She pursued a fellowship in hematology and oncology at Beth Israel Deaconess Medical Center, where she also completed a postdoctoral fellowship in cancer genetics.
Titles
- Assistant Professor
Education & Training
- Research FellowBeth Israel Deaconess Medical Center (2017)
- Clinical Fellow in Hematology/OncologyBeth Israel Deaconess Medical Center (2014)
- ResidentWeill Cornell-New York Presbyterian (2011)
- InternWeill Cornell-New York Presbyterian (2009)
- PhDAlbert Einstein College of Medicine, Cell Biology
- MDAlbert Einstein College of Medicine
Languages Spoken
- English
- Español (Spanish)
Additional Information
Professional Service
- American Society of Hematology (2007 - Present): Member
Publications
- Ito S, Potnis K, Ng D, Patel K, Sra M, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Huntington S, Stahl M, Zeidan A, Bewersdorf J, Goshua G. Cost-effectiveness of frontline eltrombopag with immunosuppressive therapy for severe aplastic anemia. Blood Red Cells & Iron 2026, 2: 100076. PMID: 42077391, PMCID: PMC13134686, DOI: 10.1016/j.brci.2026.100076.
- Aguirre L, Bewersdorf J, Liu Y, Shallis R, Boussi L, Zucenka A, Garciaz S, Bystrom R, DeAngelo D, Stone R, Luskin M, Garcia J, Winer E, Ling K, Chen E, Wadleigh M, Berton G, Stein E, Goldberg A, Mendez L, Zeidan A, Sallman D, Shimony S, Stahl M. Comparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogenetics. Blood Neoplasia 2026, 3: 100201. PMID: 41859348, PMCID: PMC12997325, DOI: 10.1016/j.bneo.2026.100201.
- Gong G, Liu J, Pandya S, Taborda C, Wiesendanger N, Price N, Byron W, Coppi A, Young P, Wiess C, Dunning H, Barganier C, Brodeur R, Fischbach N, LoRusso P, Pusztai L, Kim S, Rozenblit M, Cecchini M, Mongiu A, Mendez L, Kaftan E, Torre C, Krumholz H, Krop I, Schulz W, Lustberg M, Kunz P. Clinical Trial Patient Matching: A Real-Time, Common Data Model and Artificial Intelligence–Driven System for Semiautomated Patient Prescreening in Cancer Clinical Trials. JCO Clinical Cancer Informatics 2026, 10: e2500262. PMID: 41512229, DOI: 10.1200/cci-25-00262.
- Alhajahjeh A, Woite N, Rolles B, Stempel J, Mina A, Mendez L, Kewan T, Podoltsev N, Stahl M, Grimshaw A, Zeidan A, Bewersdorf J. Luspatercept for patients with lower-risk myelodysplastic syndromes/neoplasms: a systematic review and meta-analysis. Blood Advances 2025, 9: 6511-6523. PMID: 40966428, PMCID: PMC12767819, DOI: 10.1182/bloodadvances.2025017611.
- Hunter C, Chou A, Roeder H, Eighmy W, Bewersdorf J, Mendez L, Stahl M, Podoltsev N, Zeidan A, Shallis R. Isavuconazole provides effective and tolerable antifungal prophylaxis for patients with acute myeloid leukemia. Leukemia Research 2025, 160: 108144. PMID: 41365214, DOI: 10.1016/j.leukres.2025.108144.
- Hunter C, Cheng W, Bewersdorf J, Boddu P, Browning S, Halene S, Parker T, Huntington S, Kothari S, Mendez L, Neparidze N, Sethi T, Barbarotta L, Podoltsev N, Zeidan A, Shallis R. Feasibility, safety and outcomes of patients with newly diagnosed acute myeloid leukemia discharged ‘early’ after intensive induction. Leukemia & Lymphoma 2025, 67: 164-175. PMID: 41160735, DOI: 10.1080/10428194.2025.2578420.
- Author Correction: An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancerChen M, Zhang J, Sampieri K, Clohessy J, Mendez L, Gonzalez-Billalabeitia E, Liu X, Lee Y, Fung J, Katon J, Menon A, Webster K, Ng C, Palumbieri M, Diolombi M, Breitkopf S, Teruya-Feldstein J, Signoretti S, Bronson R, Asara J, Castillo-Martin M, Cordon-Cardo C, Pandolfi P. Author Correction: An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer. Nature Genetics 2025, 57: 2931-2931. PMID: 41125873, DOI: 10.1038/s41588-025-02394-w.
- Alhajahjeh A, Patel K, Podoltsev N, Kewan T, Stempel J, Mendez L, Seropian S, Gowda L, Huntington S, Stahl M, Zeidan A, Goshua G, Bewersdorf J. Cost-effectiveness of upfront vs delayed allogeneic hematopoietic stem cell transplant for intermediate risk AML. Blood Advances 2025, 9: 5234-5246. PMID: 40720773, PMCID: PMC12550792, DOI: 10.1182/bloodadvances.2025016532.
- Wang R, Stempel J, Shallis R, Huntington S, Zeidan A, Neparidze N, Di M, Bewersdorf J, Mendez L, Ma X, Podoltsev N. Second malignancies among older patients with classical myeloproliferative neoplasms treated with ruxolitinib. Blood Neoplasia 2025, 2: 100159. PMID: 41216598, PMCID: PMC12597058, DOI: 10.1016/j.bneo.2025.100159.
- Hidalgo Cedeno E, Germans S, Pan Z, Mendez L, Weinberg O, Xu M. PAX5 as a diagnostic tool in unconventional acute leukemia: Establishing immunohistochemical evidence of B-cell lineage. Human Pathology 2025, 163: 105903. PMID: 40782987, DOI: 10.1016/j.humpath.2025.105903.
- Bewersdorf J, Hasle V, Shallis R, Thompson E, de Menezes D, Rose S, Boss I, Mendez L, Podoltsev N, Stahl M, Kewan T, Halene S, Haferlach T, Fox B, Zeidan A. Integrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine ± Durvalumab. Therapeutic Advances In Hematology 2025, 16: 20406207251347344. PMID: 40546817, PMCID: PMC12182606, DOI: 10.1177/20406207251347344.
- Mendez L, DeAngelo D, Luskin M. Treatment of Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. Acta Haematologica 2025, 149: 61-75. PMID: 40494331, DOI: 10.1159/000546381.
- Yang M, Boye-Doe A, Ali M, Abosabie S, Barr A, Mendez L, Sharda A. RalB uncoupling from exocyst is required for endothelial Weibel-Palade body exocytosis. Molecular Biology Of The Cell 2025, 36: ar62. PMID: 40172988, PMCID: PMC12086567, DOI: 10.1091/mbc.e24-11-0493.
- Alhajahjeh A, Patel K, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Huntington S, Stahl M, Goshua G, Bewersdorf J, Zeidan A. Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AML. Leukemia & Lymphoma 2024, 66: 488-496. PMID: 39560957, PMCID: PMC12138910, DOI: 10.1080/10428194.2024.2426073.
- A review of the isocitrate dehydrogenase inhibitors in management of adult patients with AML and MDSNorman M, Yamartino K, Gerstein R, Shallis R, Mendez L, Podoltsev N, Stahl M, Eighmy W, Zeidan A. A review of the isocitrate dehydrogenase inhibitors in management of adult patients with AML and MDS. Expert Review Of Hematology 2024, 17: 755-767. PMID: 39474840, DOI: 10.1080/17474086.2024.2422554.
- Alhajahjeh A, Rotter L, Stempel J, Grimshaw A, Bewersdorf J, Blaha O, Kewan T, Podoltsev N, Shallis R, Mendez L, Stahl M, Zeidan A. Global Disparities in the Characteristics and Outcomes of Leukemia Clinical Trials: A Cross-Sectional Study of the ClinicalTrials.gov Database. JCO Global Oncology 2024, 10: e2400316. PMID: 39621951, DOI: 10.1200/go-24-00316.
- Rotter L, Alhajahjeh A, Stempel J, Grimshaw A, Bewersdorf J, Blaha O, Kewan T, Podoltsev N, Shallis R, Mendez L, Stahl M, Zeidan A. Analyzing determinants of premature trial discontinuation in leukemia clinical trials. Leukemia & Lymphoma 2024, 66: 289-297. PMID: 39440622, DOI: 10.1080/10428194.2024.2416565.
- Xie Z, Komrokji R, Al Ali N, Regelson A, Geyer S, Patel A, Saygin C, Zeidan A, Bewersdorf J, Mendez L, Kishtagari A, Zeidner J, Coombs C, Madanat Y, Chung S, Badar T, Foran J, Desai P, Tsai C, Griffiths E, Al Malki M, Amanam I, Lai C, Deeg H, Ades L, Arana Yi C, Osman A, Dinner S, Abaza Y, Taylor J, Chandhok N, Soong D, Brunner A, Carraway H, Singh A, Elena C, Ferrari J, Gallì A, Pozzi S, Padron E, Patnaik M, Malcovati L, Savona M, Al-Kali A. Risk prediction for clonal cytopenia: multicenter real-world evidence. Blood 2024, 144: 2033-2044. PMID: 38996210, PMCID: PMC11561536, DOI: 10.1182/blood.2024024756.
- Taborda C, Zeidan A, Mendez L. Clonal cytopenia of undetermined significance: definitions, risk and therapeutic targets. Frontiers In Hematology 2024, 3: 1419323. DOI: 10.3389/frhem.2024.1419323.
- Bewersdorf J, Patel K, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Stahl M, Stein E, Huntington S, Goshua G, Zeidan A. Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3-mutant acute myeloid leukemia. Leukemia & Lymphoma 2024, 65: 1136-1144. PMID: 38648559, PMCID: PMC11265977, DOI: 10.1080/10428194.2024.2344052.
- Shallis R, Wang R, Zeidan A, Huntington S, Neparidze N, Stempel J, Mendez L, Di M, Ma X, Podoltsev N. Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence. Blood Advances 2023, 7: 3213-3224. PMID: 36939371, PMCID: PMC10338212, DOI: 10.1182/bloodadvances.2022009074.
- Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid NeoplasmsXie Z, Chen E, Mendez L, Komrokji R, Zeidan A. Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms. The Cancer Journal 2023, 29: 130-137. PMID: 37195768, DOI: 10.1097/ppo.0000000000000656.
- Mendez L, Patnaik M. Clonal Hematopoiesis: Origins and determinants of evolution. Leukemia Research 2023, 129: 107076. PMID: 37075557, DOI: 10.1016/j.leukres.2023.107076.
- VanOudenhove J, Halene S, Mendez L. Is it the time to integrate novel sequencing technologies into clinical practice? Current Opinion In Hematology 2022, 30: 70-77. PMID: 36602939, DOI: 10.1097/moh.0000000000000754.
- Garcia J, Flamand Y, Penter L, Keng M, Tomlinson B, Mendez L, Koller P, Cullen N, Arihara Y, Pfaff K, Wolff J, Brunner A, Galinsky I, Bashey A, Antin J, Cutler C, Ho V, Jonas B, Luskin M, Wadleigh M, Winer E, Savell A, Leonard R, Robertson T, Davids M, Streicher H, Rodig S, Ritz J, Wu C, DeAngelo D, Neuberg D, Stone R, Soiffer R. Ipilimumab plus decitabine for patients with MDS or AML in post-transplant or transplant naïve settings. Blood 2022, 141: 1884-1888. PMID: 36332187, PMCID: PMC10122101, DOI: 10.1182/blood.2022017686.
- Daver N, Montesinos P, Aribi A, Martinelli G, Altman J, Wang E, Roboz G, Burke P, Gaidano G, Walter R, Thomas X, Jeyakumar D, DeAngelo D, Erba H, Todisco E, Begna K, Advani A, Gastaud L, de la Fuente A, Curti A, Mendez L, Vyas P, Boissel N, Vey N, Recher C, Longval T, Platzbecker U, Kapp-Schwörer S, Schliemann C, Konopleva M, Torres L, Sallman D, Marcucci G, Marconi G, Kantarjian H, Sloss C, Malcolm K, Zweidler-McKay P, Sweet K. Poster: AML-262 Pivekimab Sunirine (PVEK, IMGN632) Triplet With Azacitidine and Venetoclax Shows Broad Activity in Adverse Genetic Subsets of Relapsed/Refractory Acute Myeloid Leukemia and Reduced Infusion-Related Reactions. Clinical Lymphoma Myeloma & Leukemia 2022, 22: s132. DOI: 10.1016/s2152-2650(22)00792-3.
- Daver N, Montesinos P, Aribi A, Martinelli G, Altman J, Wang E, Roboz G, Burke P, Gaidano G, Walter R, Thomas X, Jeyakumar D, DeAngelo D, Erba H, Todisco E, Begna K, Advani A, Gastaud L, de la Fuente A, Curti A, Mendez L, Vyas P, Boissel N, Vey N, Recher C, Longval T, Platzbecker U, Kapp-Schwörer S, Schliemann C, Konopleva M, Torres L, Sallman D, Marcucci G, Marconi G, Kantarjian H, Sloss C, Malcolm K, Zweidler-McKay P, Sweet K. AML-262 Pivekimab Sunirine (PVEK, IMGN632) Triplet With Azacitidine and Venetoclax Shows Broad Activity in Adverse Genetic Subsets of Relapsed/Refractory Acute Myeloid Leukemia and Reduced Infusion-Related Reactions. Clinical Lymphoma Myeloma & Leukemia 2022, 22: s231-s232. DOI: 10.1016/s2152-2650(22)01257-5.
- Brunner A, Liu Y, Mendez L, Garcia J, Amrein P, Neuberg D, Dean E, Smith S, Stone R, Fathi A, Walter M, Graubert T, Jacoby M. P758: INHIBITION OF ATR WITH CERALASERTIB (AZD6738) FOR THE TREATMENT OF PROGRESSIVE OR RELAPSED MYELODYSPLASTIC SYNDROMES AND CHRONIC MYELOMONOCYTIC LEUKEMIA: A PHASE IB/II STUDY. HemaSphere 2022, 6: 653-654. DOI: 10.1097/01.hs9.0000845916.12740.98.
- Kukkula A, Ojala V, Mendez L, Sistonen L, Elenius K, Sundvall M. Therapeutic Potential of Targeting the SUMO Pathway in Cancer. Cancers 2021, 13: 4402. PMID: 34503213, PMCID: PMC8431684, DOI: 10.3390/cancers13174402.
- Sharda A, Bogue T, Barr A, Mendez L, Flaumenhaft R, Zwicker J. Circulating Protein Disulfide Isomerase Is Associated with Increased Risk of Thrombosis in JAK2-Mutated Myeloproliferative NeoplasmsPlasma PDI and Thrombosis in MPN. Clinical Cancer Research 2021, 27: 5708-5717. PMID: 34400417, PMCID: PMC9170286, DOI: 10.1158/1078-0432.ccr-21-1140.
- Sharda A, Barr A, Harrison J, Wilkie A, Fang C, Mendez L, Ghiran I, Italiano J, Flaumenhaft R. VWF maturation and release are controlled by 2 regulators of Weibel-Palade body biogenesis: exocyst and BLOC-2. Blood 2020, 136: 2824-2837. PMID: 32614949, PMCID: PMC7731791, DOI: 10.1182/blood.2020005300.
- Brunner A, Blonquist T, DeAngelo D, McMasters M, Fell G, Hermance N, Winer E, Lindsley R, Hobbs G, Amrein P, Hock H, Steensma D, Garcia J, Luskin M, Stone R, Ballen K, Rosenblatt J, Avigan D, Nahas M, Mendez L, McAfee S, Moran J, Bergeron M, Foster J, Bertoli C, Manning A, McGregor K, Fishman K, Kuo F, Baltay M, Macrae M, Burke M, Behnan T, Wey M, Som T, Ramos A, Rae J, Lombardi Story J, Nelson N, Logan E, Connolly C, Neuberg D, Chen Y, Graubert T, Fathi A. Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. The Lancet Haematology 2019, 7: e122-e133. PMID: 31837959, PMCID: PMC10354959, DOI: 10.1016/s2352-3026(19)30203-0.
- Mendez L, Posey R, Pandolfi P. The Interplay Between the Genetic and Immune Landscapes of AML: Mechanisms and Implications for Risk Stratification and Therapy. Frontiers In Oncology 2019, 9: 1162. PMID: 31781488, PMCID: PMC6856667, DOI: 10.3389/fonc.2019.01162.
- Nachmani D, Bothmer A, Grisendi S, Mele A, Bothmer D, Lee J, Monteleone E, Cheng K, Zhang Y, Bester A, Guzzetti A, Mitchell C, Mendez L, Pozdnyakova O, Sportoletti P, Martelli M, Vulliamy T, Safra M, Schwartz S, Luzzatto L, Bluteau O, Soulier J, Darnell R, Falini B, Dokal I, Ito K, Clohessy J, Pandolfi P. Germline NPM1 mutations lead to altered rRNA 2′-O-methylation and cause dyskeratosis congenita. Nature Genetics 2019, 51: 1518-1529. PMID: 31570891, PMCID: PMC6858547, DOI: 10.1038/s41588-019-0502-z.
- Mugoni V, Panella R, Cheloni G, Chen M, Pozdnyakova O, Stroopinsky D, Guarnerio J, Monteleone E, Lee J, Mendez L, Menon A, Aster J, Lane A, Stone R, Galinsky I, Zamora J, Lo-Coco F, Bhasin M, Avigan D, Longo L, Clohessy J, Pandolfi P. Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy. Cell Research 2019, 29: 446-459. PMID: 31024166, PMCID: PMC6796925, DOI: 10.1038/s41422-019-0162-7.
- Chen M, Zhang J, Sampieri K, Clohessy J, Mendez L, Gonzalez-Billalabeitia E, Liu X, Lee Y, Fung J, Katon J, Menon A, Webster K, Ng C, Palumbieri M, Diolombi M, Breitkopf S, Teruya-Feldstein J, Signoretti S, Bronson R, Asara J, Castillo-Martin M, Cordon-Cardo C, Pandolfi P. An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer. Nature Genetics 2018, 50: 206-218. PMID: 29335545, PMCID: PMC6714980, DOI: 10.1038/s41588-017-0027-2.
- Chen M, Wan L, Zhang J, Zhang J, Mendez L, Clohessy J, Berry K, Victor J, Yin Q, Zhu Y, Wei W, Pandolfi P. Deregulated PP1α phosphatase activity towards MAPK activation is antagonized by a tumor suppressive failsafe mechanism. Nature Communications 2018, 9: 159. PMID: 29335436, PMCID: PMC5768788, DOI: 10.1038/s41467-017-02272-y.
- Guarnerio J, Mendez L, Asada N, Menon A, Fung J, Berry K, Frenette P, Ito K, Pandolfi P. A non-cell-autonomous role for Pml in the maintenance of leukemia from the niche. Nature Communications 2018, 9: 66. PMID: 29302031, PMCID: PMC5754357, DOI: 10.1038/s41467-017-02427-x.
- Mendez L, Chen M, Pandolfi P. Molecular Genetics of APL. 2017, 41-53. DOI: 10.1007/978-3-319-64257-4_4.
- Pyzer AR, Stroopinsky D, Rosenblatt J, Anastasiadou E, Rajabi H, Washington A, Tagde A, Chu JH, Coll M, Jiao AL, Tsai LT, Tenen DE, Cole L, Palmer K, Ephraim A, Leaf RK, Nahas M, Apel A, Bar-Natan M, Jain S, McMasters M, Mendez L, Arnason J, Raby BA, Slack F, Kufe D, Avigan D. MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs. Leukemia 2017, 31: 2780-2790. PMID: 28555079, PMCID: PMC5791150, DOI: 10.1038/leu.2017.163.
- Pyzer A, Stroopinsky D, Rajabi H, Washington A, Tagde A, Coll M, Fung J, Bryant M, Cole L, Palmer K, Somaiya P, Karp Leaf R, Nahas M, Apel A, Jain S, McMasters M, Mendez L, Levine J, Joyce R, Arnason J, Pandolfi P, Kufe D, Rosenblatt J, Avigan D. MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia. Blood 2017, 129: 1791-1801. PMID: 28126925, PMCID: PMC5813734, DOI: 10.1182/blood-2016-07-730614.
- Mendez L, Sharda A, Zwicker J. Thrombophilia and Thrombocytopenia in the Pregnant Woman. 2017, 55-76. DOI: 10.1007/978-3-319-39328-5_4.
- Molecular Genetics of Acute Promyelocytic LeukemiaMendez LM, Chen M, Pandolfi PP. Molecular Genetics of Acute Promyelocytic Leukemia. In: Abla, Oussama, Lo Coco, Francesco, Sanz, Miguel A, editors. Acute Promyelocytic Leukemia. Springer 2018.
- Thrombophilia and Thrombocytopenia in the Pregnant WomanMendez LM, Sharda AV, Zwicker JI. Thrombophilia and Thrombocytopenia in the Pregnant Woman. In: Bernstein C, Takoudes T, editors. Medical Problems During Pregnancy. Springer: 2017
- Cerchietti LC, Hatzi K, Caldas-Lopes E, Yang SN, Figueroa ME, Morin RD, Hirst M, Mendez L, Shaknovich R, Cole PA, Bhalla K, Gascoyne RD, Marra M, Chiosis G, Melnick A. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. J Clin Invest 2010, 120: 4569-82. PMID: 21041953, DOI: 10.1172/JCI42869.
- Mendez LM, Polo JM, Yu JJ, Krupski M, Ding BB, Melnick A, Ye BH. CtBP is an essential corepressor for BCL6 autoregulation. Mol Cell Biol 2008, 28: 2175-86. PMID: 18212045, DOI: 10.1128/MCB.01400-07.
- Ding BB, Yu JJ, Yu RY, Mendez LM, Shaknovich R, Zhang Y, Cattoretti G, Ye BH. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 2008, 111: 1515-23. PMID: 17951530, DOI: 10.1182/blood-2007-04-087734.
- Wang X, Ding BB, Mendez LM, Papetti M, Ye BH. Re: Torlakovic et al. PU.1 protein expression has a positive linear association with protein expression of germinal centre B cell genes including BCL-6, CD10, CD20 and CD22: identification of PU.1 putative binding sites in the BCL-6 promotor. J Pathol 2005;206:312-319. J Pathol 2006, 210: 130-1; author reply 132. PMID: 16841370, DOI: 10.1002/path.2031.
Departments and Programs
Locations
Hematology Program
Smilow Cancer Hospital at Yale New Haven
35 Park Street
New Haven, CT 06511
- Hematology ProgramSmilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
Hematology Program
Smilow Cancer Hospital at Yale New Haven
35 Park Street
New Haven, CT 06511
- Hematology ProgramSmilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511